Navigation Links
Palatin Technologies, Inc. Receives $2.5 Million from AstraZeneca

CRANBURY, N.J., March 23 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that it received $2.5 million from AstraZeneca AB pursuant to the September 2009 amendment of the exclusive research collaboration and license agreement to discover, develop and commercialize compounds that target melanocortin receptors for treatment of obesity and related indications.

Payment of the $2.5 million was contingent on the successful completion by Palatin of certain tasks this quarter relating to the program.  Palatin received an initial $2.5 million upon signing the September 2009 amendment.

Separately, Palatin announced receipt of a letter from NYSE Amex determining that Palatin successfully resolved the continued listing deficiencies referenced in a December 2008 letter from NYSE Amex.  

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonists with a focus on melanocortin and natriuretic peptide receptor systems. Palatin's internally developed drug pipeline utilizes proprietary approaches to discover potent rigid conformers from flexible peptide starting points. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin Technologies' website at

SOURCE Palatin Technologies, Inc.

Back to top



SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
2. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
3. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
4. Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
5. Palatin Technologies to Present at 8th Annual BIO Investor Forum
6. Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men
7. Palatin Technologies, Inc. To Raise $2.6 Million Dollars in Registered Direct Offering
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
10. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
11. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
Post Your Comments:
(Date:10/13/2015)... 2015   Vigilant Biosciences, Inc. ("Vigilant"), a ... the early detection and intervention of cancer, announced today ... CEO, Matthew H.J. Kim , the Weaver H. ... entrepreneur who has made extraordinary contributions to the growth ... in the leadership of a company or institution. ...
(Date:10/13/2015)... Oct. 13, 2015 WuXi PharmaTech (Cayman) ... technology platform company serving the pharmaceutical, biotechnology, and ... launched a mobile version of OncoWuXi, the first ... access oncology models and data on the go.  ... at any time to identify relevant tumor models ...
(Date:10/13/2015)... , Oct. 13, 2015   Happy ... direct-to-consumer laboratory home testing kit for breast ... technologies provide an unparalleled, detailed assessment of ... milk—fats, proteins, carbs and key vitamins—all charted ... for personal health tracking.  In addition, Happy Vitals ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... ... Sir Grout of Greater Boston donated an expansive, seven room tile and ... (RMHC®). This donation was made in an effort to give back to the local ... “We believe strongly in the Ronald McDonald House Charities, and they are truly a ...
(Date:10/13/2015)... , ... October 13, 2015 , ... "My friend's son ... fists into his infected cheeks," said an inventor from Platteville, Colo. "I came up ... problems." , He developed the UNTOUCHABLE to prevent a child from rubbing or scratching ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... pain management services, today announced its partnership with WPC Healthcare , a ... disparate systems and organizes the data into an aggregated data repository necessary to ...
(Date:10/13/2015)... ... , ... According to an article published October 5th by the ... lose weight with a bariatric procedure are much less likely to develop endometrial cancer, ... anywhere from 40 to 50 percent of all endometrial cancer cases are caused by ...
(Date:10/13/2015)... ... October 13, 2015 , ... Altec ... their sponsorship of the Microsoft Dynamics AXUG, GPUG and NAVUG Summits to take ... and NAVUG Summit are independent user conferences designed and led by users to ...
Breaking Medicine News(10 mins):